KA/EN
Register
Medicines reference
Search
Search
Product

Biocan Novel Puppy

Favourites

Canine distemper virus + Canine parvovirus · Bioveta a.s.

1 form: suspension. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
Suspension · Dog Dog 1 ml
Reconstitute and inject the entire 1 ml dose subcutaneously from 6 weeks of age, regardless of weight or breed. When maternal antibodies or broader protection are relevant, follow with a compatible polyvalent Biocan Novel vaccine after 3 weeks. Annual revaccination applies when only CDV/CPV protection is required. Vaccinate healthy animals only. Not recommended during pregnancy or lactation. Recently vaccinated dogs may shed CPV-2b vaccine strain; protect susceptible non-dog carnivores and cats from exposure.
 · one dose from 6 weeks; follow-up according to the compatible polyvalent schedule		 one dose from 6 weeks; follow-up according to the compatible polyvalent schedule Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბიოკან ნოველ Puppy
№ 14-11
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Biocan Novel Puppy, Suspension

lyophilisate and solvent for injection, 1 ml dose for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.9/10
Good
vetman assessment

Biocan Novel Puppy

lyophilisate and solvent for injection, 1 ml dose for dogs
Assessed clinical scopeDog · Full dog label: early active immunisation from 6 weeks against distemper and parvovirus, with a compatible broader Biocan Novel follow-up when indicated · Subcutaneous
Care settingPreventive puppy vaccination with examination, cold-chain control and a documented follow-up plan
vetman score 7.9/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 14-11 · Verified on 21 Oct 2026

A useful early CDV/CPV bridge for young puppies, not a stand-alone lifetime programme. Its value is highest when the clinic records the next polyvalent doses and completes a guideline-concordant core series.

Regulatory and scientific credibility8.5/10

The exact one-dose presentation is registered in Georgia and has a current EU regulator record and detailed product information, although public independent evidence on this particular high-titre two-antigen formulation is limited.

Clinical efficacy7.5/10

CDV and CPV are essential core targets and the high-titre early-puppy role is clinically coherent, but one dose at six weeks is a bridge rather than a complete modern core series and must be followed according to maternal-antibody risk.

Safety and tolerability8.0/10

The expected live core-vaccine safety profile is favourable in healthy puppies, with mostly transient reactions; pregnancy or lactation use is not recommended and shed CPV-2b strain warrants hygiene around susceptible carnivores.

Clinical practicality7.5/10

The fixed 1 ml dose is simple, but reconstitution, cold chain, immediate use and the need to schedule a compatible polyvalent follow-up make it less self-contained than a complete puppy-series product.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in hypersensitivity; vaccinate clinically healthy puppies only.
  • A dose from 6 weeks is not a complete puppy series. Record and administer compatible polyvalent follow-up doses through the age at which maternal antibody no longer compromises core protection.
  • Safety during pregnancy and lactation is not established and use is not recommended.
  • Vaccinated puppies may shed the live CPV-2b strain; protect susceptible cats and other non-dog carnivores from exposure and dispose of faeces hygienically.
  • Use with other veterinary medicines or vaccines only in combinations specifically supported by the product information; otherwise decide timing case by case.
  • Observe after vaccination for local, gastrointestinal or hypersensitivity reactions and treat promptly if a systemic reaction develops.
  • Maintain the cold chain, do not freeze and administer the full reconstituted 1 ml dose immediately.
Assessment sources
  1. EU UPD Biocan Puppy2026
  2. WSAVA vaccination 20242024
  3. AAHA canine vaccination 20222022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Canine distemper virus4.1 log10 TCID50/dose Canine parvovirus5.5 log10 TCID50/dose
Formulation Type
Suspension
Administration route
Subcutaneous
Manufacturer
Bioveta a.s. · Czechia
Manufacturer (register)
Bioveta a.s., Czechia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 781, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბიოკან ნოველ Puppy
№ 14-11
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
1 ml
Reconstitute and inject the entire 1 ml dose subcutaneously from 6 weeks of age, regardless of weight or breed. When maternal antibodies or broader protection are relevant, follow with a compatible polyvalent Biocan Novel vaccine after 3 weeks. Annual revaccination applies when only CDV/CPV protection is required. Vaccinate healthy animals only. Not recommended during pregnancy or lactation. Recently vaccinated dogs may shed CPV-2b vaccine strain; protect susceptible non-dog carnivores and cats from exposure.
 Dog Any weight Subcutaneous one dose from 6 weeks; follow-up according to the compatible polyvalent schedule
EU UPD Biocan Puppy
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Biocan Novel Puppy - official product information
EU Union Product Database, 2026

Canine distemper virus: No dose supported by a publicly verifiable source yet

Canine parvovirus: No dose supported by a publicly verifiable source yet

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 21 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗